SLC2A4RG

Summary

SLC2A4RG (SLC2A4 regulator, HGNC:15930) is a protein-coding gene on chromosome 20q13.33, encoding SLC2A4 regulator (Q9NR83). Transcription factor involved in SLC2A4 and HD gene transactivation.

The protein encoded by this gene is a nuclear transcription factor involved in the activation of the solute carrier family 2 member 4 gene. The encoded protein interacts with another transcription factor, myocyte enhancer factor 2, to activate transcription of this gene.

Source: NCBI Gene 56731 — RefSeq curated summary.

At a glance

• GWAS associations: 20
• Clinical variants (ClinVar): 80 total
• MANE Select transcript: NM_020062

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15930
Approved symbol	SLC2A4RG
Name	SLC2A4 regulator
Location	20q13.33
Locus type	gene with protein product
Status	Approved
Aliases	GLUT4EF, GEF, HDBP1, Si-1-2, Si-1-2-19
Ensembl gene	ENSG00000125520
Ensembl biotype	protein_coding
OMIM	609493
Entrez	56731

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 7 protein_coding, 7 protein_coding_CDS_not_defined

ENST00000266077, ENST00000473157, ENST00000474248, ENST00000482718, ENST00000485897, ENST00000491109, ENST00000493772, ENST00000496425, ENST00000872204, ENST00000922156, ENST00000922157, ENST00000946584, ENST00000946585, ENST00000946586

RefSeq mRNA: 1 — MANE Select: NM_020062 NM_020062

CCDS: CCDS13537

Canonical transcript exons

ENST00000266077 — 8 exons

Exon	Start	End
ENSE00000593416	63740377	63740531
ENSE00000856636	63739776	63740038
ENSE00003481355	63741869	63742056
ENSE00003524399	63742699	63742790
ENSE00003541645	63742879	63744050
ENSE00003547685	63741370	63741479
ENSE00003645822	63742130	63742230
ENSE00003683365	63742336	63742615

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 98.42.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 43.7063 / max 336.7348, expressed in 1788 samples.

FANTOM5 promoters (14 alternative TSS)

Promoter ID	TPM avg	Samples expressed
185866	11.6200	1714
185872	10.8816	1555
185869	9.7163	1644
185879	5.7672	1405
185868	1.4480	806
185878	1.0193	606
185874	0.7798	246
185876	0.5415	304
185877	0.4412	259
185867	0.4032	230

Top tissues by expression

280 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	98.42	gold quality
right lobe of liver	UBERON:0001114	98.21	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.57	gold quality
right coronary artery	UBERON:0001625	97.54	gold quality
popliteal artery	UBERON:0002250	97.45	gold quality
mucosa of stomach	UBERON:0001199	97.44	gold quality
skin of abdomen	UBERON:0001416	97.44	gold quality
tibial artery	UBERON:0007610	97.44	gold quality
descending thoracic aorta	UBERON:0002345	97.30	gold quality
skin of leg	UBERON:0001511	97.28	gold quality
metanephros cortex	UBERON:0010533	97.19	gold quality
aorta	UBERON:0000947	97.07	gold quality
left uterine tube	UBERON:0001303	97.07	gold quality
ectocervix	UBERON:0012249	97.05	gold quality
right ovary	UBERON:0002118	97.02	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	97.02	gold quality
lower esophagus mucosa	UBERON:0035834	96.96	gold quality
muscle layer of sigmoid colon	UBERON:0035805	96.88	gold quality
thoracic aorta	UBERON:0001515	96.83	gold quality
ascending aorta	UBERON:0001496	96.82	gold quality
left ovary	UBERON:0002119	96.82	gold quality
left coronary artery	UBERON:0001626	96.79	gold quality
lower esophagus muscularis layer	UBERON:0035833	96.74	gold quality
lower esophagus	UBERON:0013473	96.73	gold quality
granulocyte	CL:0000094	96.70	gold quality
tibial nerve	UBERON:0001323	96.68	gold quality
endocervix	UBERON:0000458	96.53	gold quality
body of uterus	UBERON:0009853	96.28	gold quality
coronary artery	UBERON:0001621	96.11	gold quality
tendon of biceps brachii	UBERON:0008188	95.99	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.82

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
SLC2A4	Activation

JASPAR motifs

Motif	Name	Family
MA2539.1	SLC2A4RG	Factors with multiple dispersed zinc fingers

JASPAR matrix evidence (PMIDs): PMID:39605320

miRNA regulators (miRDB)

68 targeting SLC2A4RG, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-4671-3P	99.88	72.46	1045
HSA-MIR-4728-5P	99.85	69.39	4718

Literature-anchored findings (GeneRIF, showing 5)

• HDBP1 and HDBP2 are novel transcription factors shuttling between nucleus and cytoplasm and bind to the specific GCCGGCG, which is an essential cis-element for HD gene expression in neuronal cells (PMID:14625278)
• GEF and MEF2A have roles in regulating the GLUT4 promoter (PMID:14630949)
• Exercise increases MEF2 and GEF DNA binding and imply that these transcription factors could be potential targets for modulating GLUT4 expression in human skeletal muscle. (PMID:16368714)
• our results demonstrate that nuclear SLC2A4RG induces cell apoptosis in a new manner via direct transactivation of caspase-3 caspase-6 in glioma, but the interaction with 14-3-3theta; will result in sequestration of SLC2A4RG in the cytoplasm and then promote tumor progression. (PMID:30686753)
• KRAS K104 modification affects the KRAS(G12D)-GEF interaction and mediates cell growth and motility. (PMID:33060649)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
drosophila_melanogaster	Glut4EF	FBGN0267336

Paralogs (2): ZNF704 (ENSG00000164684), ZNF395 (ENSG00000186918)

Protein

Protein identifiers

SLC2A4 regulator — Q9NR83 (reviewed: Q9NR83)

Alternative names: GLUT4 enhancer factor, Huntington disease gene regulatory region-binding protein 1

All UniProt accessions (1): Q9NR83

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor involved in SLC2A4 and HD gene transactivation. Binds to the consensus sequence 5’-GCCGGCG-3'.

Subunit / interactions. Interacts with MEF2A.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. According to PubMed:14630949, expressed in heart, skeletal muscle, liver, kidney and pancreas; undetectable in lung, placenta or brain. According to PubMed:14625278, ubiquitously expressed, with lowest expression in brain and ileum.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9NR83-1	1	yes
Q9NR83-4	2
Q9NR83-3	3

RefSeq proteins (1): NP_064446* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR052253	CR1/CR2-DNA-binding_regulator	Family

UniProt features (24 total): mutagenesis site 4, region of interest 3, helix 3, modified residue 2, splice variant 2, sequence conflict 2, short sequence motif 2, compositionally biased region 2, chain 1, zinc finger region 1, sequence variant 1, strand 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
9Z44	X-RAY DIFFRACTION	7.2
7DTA	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NR83-F1	60.04	0.16

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 268, 264

Mutagenesis-validated functional residues (4):

Position	Phenotype
257	nuclear; when associated with a-260.
260	nuclear; when associated with a-257.
273	cytoplasmic; when associated with a-276.
276	cytoplasmic; when associated with a-273.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 117 (showing top): TGCACTT_MIR519C_MIR519B_MIR519A, BLALOCK_ALZHEIMERS_DISEASE_UP, DANG_BOUND_BY_MYC, NUYTTEN_EZH2_TARGETS_DN, NUYTTEN_NIPP1_TARGETS_DN, GCACTTT_MIR175P_MIR20A_MIR106A_MIR106B_MIR20B_MIR519D, NIKOLSKY_BREAST_CANCER_20Q12_Q13_AMPLICON, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, CACTGCC_MIR34A_MIR34C_MIR449, MARTENS_TRETINOIN_RESPONSE_DN, CHICAS_RB1_TARGETS_SENESCENT, CHICAS_RB1_TARGETS_CONFLUENT, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, DACH1_TARGET_GENES, FOXN3_TARGET_GENES

GO Biological Process (2): regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (5): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity (GO:0003700), zinc ion binding (GO:0008270), DNA binding (GO:0003677), metal ion binding (GO:0046872)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), nuclear speck (GO:0016607)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	2
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
transcription by RNA polymerase II	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
cis-regulatory region sequence-specific DNA binding	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
transition metal ion binding	1
nucleic acid binding	1
cation binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

1884 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC2A4RG	SLC2A4	P14672	747
SLC2A4RG	MEF2A	Q02078	740
SLC2A4RG	ZGPAT	Q8N5A5	658
SLC2A4RG	MEF2D	Q14814	651
SLC2A4RG	KANSL3	Q9P2N6	593
SLC2A4RG	LIME1	Q9H400	570
SLC2A4RG	MEF2C	Q06413	552
SLC2A4RG	HFM1	A2PYH4	547
SLC2A4RG	DYNC1I1	O14576	469
SLC2A4RG	TEDC2	Q7L2K0	469
SLC2A4RG	CROCC2	H7BZ55	460
SLC2A4RG	EXOC7	Q9UPT5	457
SLC2A4RG	RAPGEF1	Q13905	445
SLC2A4RG	EXOC3	O60645	436
SLC2A4RG	RHOQ	P17081	435
SLC2A4RG	EXOC4	Q96A65	435

IntAct

0 interactions, top by confidence:

BioGRID (4): SLC2A4RG (Affinity Capture-RNA), SLC2A4RG (Affinity Capture-RNA), SLC2A4RG (Reconstituted Complex), HDAC5 (Reconstituted Complex)

ESM2 similar proteins: A0A0U1RR11, A0A0U1RRI6, A6NCS6, A6NJG2, B0BN44, D3YXK1, E9PY61, E9Q0B3, F5H4A9, O00220, O00221, P09038, P0DPI3, P22083, P98077, Q08AU9, Q2M2W7, Q2M3V2, Q2TBI2, Q5F267, Q5FW56, Q5IS69, Q5R866, Q5T4W7, Q5TM52, Q5U4P2, Q5VTJ3, Q659K9, Q673H1, Q69ZB3, Q6AYE8, Q6IPT2, Q6PJ61, Q7RTU4, Q7TSX9, Q7YR31, Q80SU3, Q86SH2, Q86Y97, Q8NBR0

Diamond homologs: Q1LY51, Q6DFC8, Q6ZNC4, Q9ERQ3, Q9H8N7, Q9NR83

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

80 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	61
Likely benign	7
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

882 predictions. Top by Δscore:

Variant	Effect	Δscore
20:63740529:GAG:G	donor_gain	1.0000
20:63740533:T:G	donor_loss	1.0000
20:63741477:CAGGT:C	donor_loss	1.0000
20:63741478:AGGTA:A	donor_loss	1.0000
20:63741479:GGTA:G	donor_loss	1.0000
20:63741480:GTAA:G	donor_loss	1.0000
20:63742128:A:AG	acceptor_gain	1.0000
20:63742129:G:GG	acceptor_gain	1.0000
20:63742129:G:GT	acceptor_loss	1.0000
20:63742129:GA:G	acceptor_gain	1.0000
20:63742335:GGA:G	acceptor_gain	1.0000
20:63742694:TGTA:T	acceptor_loss	1.0000
20:63742697:A:AG	acceptor_gain	1.0000
20:63742697:A:T	acceptor_loss	1.0000
20:63742697:AG:A	acceptor_gain	1.0000
20:63742697:AGG:A	acceptor_gain	1.0000
20:63742698:G:GA	acceptor_gain	1.0000
20:63742698:GG:G	acceptor_gain	1.0000
20:63742698:GGG:G	acceptor_gain	1.0000
20:63742698:GGGC:G	acceptor_gain	1.0000
20:63742698:GGGCT:G	acceptor_gain	1.0000
20:63742788:GAG:G	donor_gain	1.0000
20:63742791:G:GG	donor_gain	1.0000
20:63742792:T:A	donor_loss	1.0000
20:63742864:T:TA	acceptor_gain	1.0000
20:63742872:C:CA	acceptor_gain	1.0000
20:63742875:A:AG	acceptor_gain	1.0000
20:63742875:ACAG:A	acceptor_gain	1.0000
20:63742877:A:AG	acceptor_gain	1.0000
20:63742877:A:T	acceptor_loss	1.0000

AlphaMissense

2448 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:63742960:G:C	W378C	1.000
20:63742960:G:T	W378C	1.000
20:63742154:T:C	C202R	0.999
20:63742162:G:C	W204C	0.999
20:63742162:G:T	W204C	0.999
20:63742223:C:G	H225D	0.999
20:63742376:T:C	F241L	0.999
20:63742378:C:A	F241L	0.999
20:63742378:C:G	F241L	0.999
20:63742904:T:A	C360S	0.999
20:63742904:T:C	C360R	0.999
20:63742905:G:C	C360S	0.999
20:63742940:T:A	W372R	0.999
20:63742940:T:C	W372R	0.999
20:63742942:G:C	W372C	0.999
20:63742942:G:T	W372C	0.999
20:63742943:T:A	C373S	0.999
20:63742943:T:C	C373R	0.999
20:63742944:G:A	C373Y	0.999
20:63742944:G:C	C373S	0.999
20:63742945:C:G	C373W	0.999
20:63742952:T:A	C376S	0.999
20:63742952:T:C	C376R	0.999
20:63742953:G:A	C376Y	0.999
20:63742953:G:C	C376S	0.999
20:63742954:C:G	C376W	0.999
20:63742958:T:A	W378R	0.999
20:63742958:T:C	W378R	0.999
20:63742963:G:C	K379N	0.999
20:63742963:G:T	K379N	0.999

dbSNP variants (sampled 300 via entrez): RS1000571128 (20:63741105 C>T), RS1001612819 (20:63741637 G>A,T), RS1002346763 (20:63740364 T>A,C,G), RS1002692479 (20:63740914 G>A,T), RS1002763630 (20:63741851 G>C,T), RS1003373801 (20:63739678 G>A,T), RS1003748928 (20:63743471 A>G), RS1003919478 (20:63743612 C>T), RS1004469764 (20:63739964 G>A), RS1004502859 (20:63742860 C>T), RS1006149382 (20:63740608 C>A,G,T), RS1006236415 (20:63741678 C>T), RS1006519393 (20:63740857 G>A), RS1006539909 (20:63741170 C>T), RS1007063388 (20:63741373 C>T)

Disease associations

OMIM: gene MIM:609493 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

20 associations (top):

Study	Trait	p-value
GCST000879_42	Crohn’s disease	3.000000e-15
GCST000964_24	Ulcerative colitis	2.000000e-10
GCST001725_68	Inflammatory bowel disease	1.000000e-23
GCST001942_22	Prostate cancer	4.000000e-16
GCST004131_34	Inflammatory bowel disease	3.000000e-26
GCST004132_110	Crohn’s disease	3.000000e-13
GCST004133_15	Ulcerative colitis	9.000000e-17
GCST005531_20	Multiple sclerosis	4.000000e-09
GCST007429_85	Lung function (FVC)	6.000000e-31
GCST007432_203	FEV1	2.000000e-26
GCST007563_15	Allergic disease (asthma, hay fever or eczema)	3.000000e-08
GCST007564_6	Asthma or allergic disease (pleiotropy)	3.000000e-10
GCST008916_69	Asthma	3.000000e-09
GCST009597_288	Multiple sclerosis	4.000000e-14
GCST010002_71	Refractive error	1.000000e-14
GCST010143_12	Meat-related diet	7.000000e-09
GCST010241_87	Apolipoprotein A1 levels	4.000000e-13
GCST010243_63	Apolipoprotein B levels	3.000000e-08
GCST010245_44	LDL cholesterol levels	7.000000e-09
GCST012232_38	Lipoprotein (a) levels	4.000000e-11

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0004312	vital capacity
EFO:0004314	forced expiratory volume
EFO:0008111	diet measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004615	apolipoprotein B measurement
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0006925	lipoprotein A measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases methylation	3
sodium arsenite	increases expression, decreases expression	2
Air Pollutants	affects expression, increases abundance, increases expression	2
Tretinoin	decreases expression, increases expression	2
Valproic Acid	decreases expression, increases expression	2
Cyclosporine	decreases expression	2
bisphenol F	affects cotreatment, increases expression	1
bisphenol A	affects expression	1
geraniol	decreases expression	1
lead acetate	increases expression	1
beta-lapachone	decreases expression, increases expression	1
cobaltous chloride	decreases expression	1
periodate-oxidized adenosine	affects expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
tamibarotene	increases expression	1
di-n-butylphosphoric acid	affects expression	1
K 7174	decreases expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
jinfukang	increases expression	1
NSC 689534	affects binding, decreases expression	1
(+)-JQ1 compound	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Sunitinib	decreases expression	1
Troglitazone	decreases expression	1
Copper	affects binding, decreases expression	1
Coumestrol	affects cotreatment, increases expression	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Diazinon	increases methylation	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TM82	HAP1 SLC2A4RG (-)	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer